This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wednesday's Small-Cap Winners & Losers

Updated from 1:20 p.m. EDT

Vyyo (VYYO), a communications-equipment maker, jumped almost 13% Wednesday on word it will receive $35 million in new financing from Goldman Sachs (GS).

Half of the unsecured note, which has a $10 per-share conversion price, will pay off pre-existing bonds held by Goldman. The other half will be used to speed deployment of the Norcross, Ga., company's spectrum overlay product (which boosts the bandwidth of existing cable-network infrastructure) and related services. Shares were gaining 97 cents to $8.44.

Industrial Services of America (IDSA) catapulted 23% after the Louisville, Ky., company said it earned $730,000, or 20 cents a share, in the fourth quarter compared with 12 cents a share a year ago. IDSA, which sells waste- and recycling-management services, was up $1.35 to $7.22.

Micronetics (NOIZ) said a major defense OEM (original equipment manufacturer) ordered an unspecified number of its voltage-controlled oscillators for use on dual-sensor handheld mine-detection systems. Terms weren't disclosed. Shares of the Hudson, N.H., company were leaping 73 cents, or 10%, to $8.01.

The Chinese government granted Origin Agritech (SEED) around $1.1 million to build a hybrid-seed production facility near Beijing, construction for which should finish by year-end. Shares were rising 46 cents, or 5.3%, to $9.13.

Gaming Partners International (GPIC) dropped after the Las Vegas-based outfit said it asked for a year-end filing extension from the Securities and Exchange Commission because it's currently evaluating accounting errors expected to result in "material weaknesses." Shares were sliding $2.51, or 12.2%, to $18.10.

CV Therapeutics (CVTX) tumbled again after a Citigroup analyst cut the biotech company's rating to sell from hold, citing poor results from new-indication testing of its Ranexa drug, the complete results of which were publicized Tuesday. First Albany downgraded the Palo Alto, Calif., as well -- to neutral from strong buy. Deutsche Bank had slapped on a sell rating Monday. Shares were off 67 cents, or 8.4%, to $7.29.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,926.78 +121.98 0.69%
S&P 500 2,075.61 +4.96 0.24%
NASDAQ 4,775.84 +10.46 0.22%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs